Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 5,141 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: AIDS (Acquired Immunodeficiency Syndrome) Clear all

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV), Placebo/QHPV; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 7 Years to 12 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 32
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 24 more

Conditions: Substance Use
Interventions: Integrated Intervention to Promote PrEP Uptake, Standard Treatment Condition; Behavioral · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: KP-1461; Drug
Lead sponsor: Koronis Pharmaceuticals.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 30
States / cities: Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 25 more

Conditions: HIV -1 Infection, Methamphetamine Use
Interventions: Oral Methamphetamine, Placebo oral capsule; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more

Conditions: HIV in Adults
Interventions: Atazanavir, Cobicistat, Active Pharmaceutical Ingredient; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Woburn, Massachusetts

Conditions: Infection, Human Immunodeficiency Virus
Interventions: dolutegravir 50 mg OAD, darunavir 800mg OAD, ritonavir 100mg OAD; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 33
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 25 more

Conditions: HIV, Inflammation
Interventions: Assess Safety, Effect of drug on viral load, Effect of drug on T-cell count, Effect of drug on inflammatory biomarkers; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer
Interventions: gemcitabine hydrochloride, leucovorin calcium, fluorouracil, nelfinavir mesylate, stereotactic body radiation therapy, hypofractionated radiation therapy, therapeutic conventional surgery; Drug · Radiation · Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: HIV, Healthy Volunteers
Interventions: [6,6-2H2]-glucose; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic HIV Infection
Interventions: 426c.Mod.Core-C4b, Adjuvant 3M-052-AF+Alum; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 4 more

Conditions: Lung Inflammation, HIV Seropositivity
Interventions: ECIGS, mobile contingency management (mCM), Usual brand; Other · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Seropositivity, Adherence, Medication
Interventions: MI sessions, TMQQ, Type of compensation; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Fomivirsen sodium, Ganciclovir; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Los Angeles, California • Pasadena, California • San Diego, California + 14 more

Conditions: HIV Infection, Hepatitis C Infection, Fibrosis, Inflammation
Interventions: Not listed
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: HIV Infections, HIV Wasting Syndrome
Interventions: Nandrolone decanoate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 20
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 14 more

Conditions: Human Immunodeficiency Virus (HIV) Infection
Interventions: Islatravir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Insulin Resistance, Cardiovascular Diseases, Heart Diseases, HIV Infections, Hypertriglyceridemia, Hyperlipidemia
Interventions: Acipimox; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Indinavir sulfate, Nelfinavir mesylate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Birmingham, Alabama • San Diego, California • Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Fat Emulsion 2%, Fat Emulsion 20%; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: East Orange, New Jersey

Conditions: HIV
Interventions: Navigator enhanced case-management, Forensic AIDS Project; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Peldesine; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cervical Cancer
Interventions: Health-Literacy Focused Education Session; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acquired Immunodeficiency Syndrome, HIV Infection
Interventions: PCLUS 3-18 MN, PCLUS 6.1 MN; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

Pre-exposure Prophylaxis (PrEP) Uptake and Adherence Intervention for Women with Trauma-related Conditions

Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients

Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

Taste Properties of Atazanavir and Cobicistat

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)

Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Use of Labeled Glucose to Study Lymphocyte Replication and Survival in HIV-Infected Patients

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers

Supporting Health Behavior Among Persons Living With HIV Using Tech, MOST, and Behavioral Economics

A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )

Study on Immunopathogenesis in HIV and Hepatitis C Coinfection

A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV

Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients

A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)

The Navigator Project

A Study of Peldesine (BCX-34) in HIV-Infected Patients

Community-Based Cervical Cancer Prevention and Education Among Women Living With HIV

Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection